logo

For the Inventor, By the Inventor

Chita, Japan

Katsuomi Ichikawa

This inventor holds 6 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 2000-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katsuomi Ichikawa. Retrieved from https://idiyas.com/inventor/katsuomi-ichikawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Aichi-ken, JP (2000 - 2001)
  • Okazaki, JP (2001 - 2002)
  • Chita-gun, JP (2002)

Company Filing History:

goldMedal6 out of 4,486 
 
Pfizer Corporation
 patents

Years Active: 2000-2002

Loading Chart...
6 patents (USPTO):Explore Patents
1. 6416979 - 5-substituted picolinic acid compounds production by Marasmiellus sp (2002-07-09),
2. 6391616 - Oidiodendron strain for the production of terpenoid lactone compounds (2002-05-21),
3. 6225339 - Terpenoid lactone compounds and their production process (2001-05-01),
4. 6221899 - Terpenoid lactone compounds and their production process (2001-04-24),
5. 6194442 - 5-substituted picolinic acid compounds and their method of use (2001-02-27),
6. 6034107 - 5-Substituted picolinic acid compounds and their production process (2000-03-07),

Title: Katsuomi Ichikawa: Innovator in Terpenoid Lactone Compounds

Introduction

Katsuomi Ichikawa is a notable inventor based in Chita-gun, Japan. He has made significant contributions to the field of pharmaceutical compounds, particularly in the production of terpenoid lactone compounds. With a total of 6 patents to his name, Ichikawa's work has implications for the treatment of various diseases.

Latest Patents

One of Ichikawa's latest patents involves the production of 5-substituted picolinic acid compounds by utilizing Marasmiellus sp - Oidiodendron strain. This innovative process allows for the cultivation of FERM BP-5778, followed by the isolation of terpenoid lactone compounds from the fermentation broth. The resulting pharmaceutical composition is particularly useful in treating IL-1 and TNF mediated diseases.

Career Highlights

Ichikawa is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to focus on the development of new therapeutic compounds that can address unmet medical needs.

Collaborations

Ichikawa has collaborated with several talented individuals in his field, including Nakao Kojima and Hiroyuki Nishida. These collaborations have further enhanced the innovative potential of his research.

Conclusion

Katsuomi Ichikawa's contributions to the field of terpenoid lactone compounds exemplify the impact of dedicated inventors in the pharmaceutical industry. His ongoing work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…